BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Merck’s Keytruda Nets Another Win in Melanoma

  The approval of Keytruda also now includes stage III melanoma following complete resection for pediatric patients 12 years and up.

  December 6, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Trials Show Hope on the Horizon for Dravet Syndrome, Glioblastoma

  An investigational drug for Dravet syndrome is showing promise in treating the progressive form of genetic epilepsy.

  December 6, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Adicet Bio’s Off-the-Shelf Drug Showing Positive Early Signals

  ADI-001 generated positive early responses from three of four evaluable participants, two of whom achieved complete responses while one had a partial response that researchers logged as “near complete.”

  December 6, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Traversing the Wnt Pathway with Intellectual Curiosity and Collaboration

  Surrozen’s ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.

  December 6, 2021

   · 

  10 min read

   · 

  Heather McKenzie
• 

  Drug Development

  New Mesoblast Data Offers Hope for High-Risk Heart Patients

  The latest updates from Mesoblast Limited’s Phase III trial on rexlemestrocel-L show that the drug provides the highest benefit when used in patients with certain types of chronic heart failure.

  December 6, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  NanoMosaic Scores Nearly $41 Million to Overcome Proteomic Analysis Bottleneck

  NanoMosaic plans to use the funds raised to continue building its commercial infrastructure, developing its applications, and advancing diagnostic collaborative development programs.

  December 6, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Aeglea Rare Disease Drug Dazzles in Biomarker Data, Misses on Clinical Benefit

  Austin, Texas-based Aeglea Biotherapeutics reported what initially appears to be positive outcomes for its Phase III PEACE trial of pegzilarginase in Arginase 1 Deficiency (ARG1-D).

  December 6, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Engrafting Bacteria for Therapeutic Advantage in Kidney-Related Diseases

  Proof of concept for the Genetically Engineered Microbial Medicines (GEMM) platform came in a recent first-in-human, Phase I trial.

  December 6, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  Policy

  Reata Rocked by FDA Comments Ahead of AdComm Meeting for Alport Syndrome Drug

  In the staff documents, the FDA scientists expressed concerns over the Reata clinical data that was submitted.

  December 6, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Life Sciences Funding Remains Strong as 2021 Winds Down

  Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.

  December 6, 2021

   · 

  2 min read

   · 

  Ellen Camacho